Low-dose IL-2 for chronic hives that don't respond to usual treatment
Part of Immune system & allergy, Skin clinical trials.
This study tests a low-dose immune therapy (interleukin-2) for people with chronic hives that don't get better with standard allergy pills. If you are an adult with ongoing hives and itching despite daily antihistamines, this trial might offer a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 74 years old
- You have had chronic hives for at least 3 months
- You still get hives and itching even after taking allergy pills every day for 2 weeks or more
- You can keep a daily symptom log throughout the study
- You are not pregnant, breastfeeding, or planning to become pregnant within the next 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection (CM512) for people with chronic spontaneous urticaria, also known as chronic hives. If you have had itchy hives for at least 6 weeks despite taking regular antihistamines, this study may help find a new treatment option.
This trial tests a new medication called THB335 for people with chronic spontaneous urticaria (CSU), which causes hives and itching for months without a clear cause. The study will see if the drug can reduce hives and itching better than a placebo (a pill with no active medicine).
This study tests whether a new drug called MG-K10 can help people with chronic hives (itchy welts) that haven't improved with standard allergy medications. MG-K10 works differently than regular allergy pills, targeting a specific immune pathway that causes hives.
This trial tests an experimental medicine for chronic hives (called chronic spontaneous urticaria). It is for people whose hives still bother them about once or twice a month despite daily treatment, and who do not have heart problems.
This study tests a new oral medication (TLL-018) for people with chronic spontaneous urticaria (hives that last more than 6 weeks) who still have symptoms despite taking antihistamines. The goal is to see if the drug can reduce itching and hives better than placebo.
This study tests a new drug, TLL-018, for people with moderate-to-severe chronic hives (CSU) that don't respond well to standard antihistamines. The goal is to see if it works quickly to reduce itching and hives.
Hear when a new Chronic Spontaneous Uriticaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.